About Previse
Previse is a Healthcare company based in Baltimore (United States) founded in 2018 by Dan Lunz and Stephen Meltzer, and was acquired by Castle Biosciences in May 2025. Cancer detection and prevention solutions are developed by Previse. It operates on a HealthTech model. Previse has raised $5.39 million across 3 funding rounds from investors including Castle Biosciences and National Institute of Diabetes and Digestive and Kidney Diseases. Its chief executive, as recorded, is Dan Lunz. Previse offers products and services including Esopredict. Its focus areas include Diagnostics and Cancer Detection. Its legal entity is Castle Biosciences. Its competitors include PAVmed, Lucid Diagnostics and CapNostics; 1 of its 3 listed competitors has raised funding.
Company details
Solutions for earlier cancer detection are developed by Previse, focusing initially on esophageal cancer. Proprietary epigenetic biomarkers and data science are utilized to support diverse clinical studies globally. Precision medicine approaches are employed to predict and prevent cancer progression, particularly for conditions like Barretts esophagus. The healthcare sector is primarily targeted with innovative diagnostic tools.
- Headquarters Baltimore, United States
- Founders Dan Lunz, Stephen Meltzer
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website previsedx.com
- Social LinkedIn
- Acquired by Castle Biosciences (May 2025)
- Legal Name Castle Biosciences
- Total Equity Funding$5.39M (USD)
in 3 rounds
- Latest Funding Round$1.8M (USD), Grant
Oct 2023
- InvestorsCastle Biosciences
& 1 more
- Acquired byCastle Biosciences
(May 2025)
Products & Services of Previse
Previse offers a comprehensive portfolio of products and services, including Esopredict.
Personalized guidance for Barrett’s esophagus surveillance is provided.
Funding Insights of Previse
Previse has successfully raised a total of $5.39M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.8 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.39M
- Total Rounds 3
- Last Round Grant — $1.8M
- First Round $2.39M
(Dec 2019)
- Investors Count 1
All 3 funding rounds of Previse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $1.8M | Grant | – | – | |
| Mar 2023 | $3M | Seed | – | – | – |
| Dec 2019 | $2.39M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Previse
Previse has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Castle Biosciences and National Institute of Diabetes and Digestive and Kidney Diseases.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research and health information on diabetes and kidney diseases are provided by NIDDK. | 1950 | niddk.nih.gov | United States | |
Diagnostic tests for cancer prognosis are provided. | 2008 | castlebiosciences.com | Friendswood, United States |
Investor details for Previse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Previse
2 people are tracked at Previse (2 in leadership).
| Name | Role | Group |
|---|---|---|
Dan Lunz | Co-Founder & CEO | Leadership |
Stephen Meltzer | Co-Founder | Leadership |
Complete people profiles for Previse
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Previse
4 dated milestones of Previse across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Previse is founded.
- Funding First funding round of $2.4M.
- Funding Latest funding round, Grant, of $1.8M.
- Exit Acquired by Castle Biosciences.
Competitors of Previse
Previse has 3 listed competitors in our database, 1 of them funded. They include PAVmed, Lucid Diagnostics and CapNostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pavmed.com | 2014 | New York, United States | $845,000 | 107 | Developer of medical devices and biomarkers to detect various diseases | |
| luciddx.com | 2018 | New York, United States | 74 | Diagnostic kits for esophageal cancer biomarkers are developed. | ||
| capnostics.com | 2013 | Newtown Square, United States | FDA-cleared swallowable device is used for non-endoscopic GI screening. |
Detailed competitors of Previse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Previse
The website of Previse (previsedx.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 29.9% vs previous month
Top companies in Gastroenterology
3 companies that operate in the same segment as Previse (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Previse
Complete news archive for Previse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Previse
Previse was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Previse is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Dan Lunz is the CEO of Previse, as recorded in our data. They have also founded this company.
Previse is a funded company, having raised a total of $5.39M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.39M, raised on Dec 2019.
Solutions for earlier cancer detection are developed by Previse, focusing initially on esophageal cancer. Proprietary epigenetic biomarkers and data science are utilized to support diverse clinical studies globally. Precision medicine approaches are employed to predict and prevent cancer progression, particularly for conditions like Barretts esophagus. The healthcare sector is primarily targeted with innovative diagnostic tools.
Previse's top competitors include Lucid Diagnostics, PAVmed and CapNostics.
Previse offers Esopredict.
Previse has 2 investors. Key investors include Castle Biosciences, and National Institute of Diabetes and Digestive and Kidney Diseases.
Previse operates through Castle Biosciences.
Yes. Previse was acquired by Castle Biosciences in May 2025.